newsfilter
← Latest News
PR Newswire·

New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026

BIOA
  • BioArctic partner Eisai will present new clinical & real-world evidence on lecanemab (Leqembi) at the Alzheimer's Association International Conference (AAIC) in London from July 12-15, 2026.
  • Presentations will cover the subcutaneous formulation, long-term use in diverse patient groups, maintenance dosing, & at-home administration.
  • BioArctic will participate in the July 14 Plenary Session regarding the prevalence of Alzheimer's pathology & present strategies for assessing clinical progression in α-synucleinopathies like Parkinson's disease.
  • Key oral sessions include data on subcutaneous treatment emerging evidence on July 12 & LEADER study real-world results on July 14 regarding maintenance dosing & at-home subcutaneous use.
  • Updates on the Phase 3 AHEAD 3-45 preclinical Alzheimer's study will be provided, focusing on participant retention & engagement.
  • Multiple additional oral presentations will address ARIA management, sex-based outcomes, external controls, tau biomarkers, racial differences, & safety surveillance.
  • A comprehensive list of poster presentations will be displayed July 12-15 covering ride-share services, long-term persistence, subcutaneous initiation, cost analysis, & economic impact.
  • Eisai will host a symposium for healthcare professionals on July 14 titled "Early Intervention in Alzheimer's Disease: Building the Evidence from Pathology to Practice."
  • Leqembi is currently approved in 53 countries with applications pending in 6 others & intravenous maintenance dosing approved in 8 countries including the US, UK, China, & Japan.
  • In the US, Leqembi Iqlik is approved for subcutaneous maintenance dosing, while Japan & China have received or are reviewing applications for subcutaneous formulations.
  • The US FDA granted Priority Review to a supplemental Biologics License Application for a subcutaneous starting dose on January 2026, with an extended PDUFA date of August 24, 2026.
  • The ongoing AHEAD 3-45 study in preclinical Alzheimer's disease was fully recruited in October 2024 & is a public-private partnership involving Eisai, Biogen, & the NIH.
  • The Tau NexGen clinical study for Dominantly Inherited Alzheimer's disease, using lecanemab as backbone therapy, has been ongoing since January 2022.
  • BioArctic holds commercialization rights for lecanemab in the Nordic region & receives sales milestones & royalties from Eisai's global sales.
  • BioArctic's B shares (BIOA B) are listed on Nasdaq Stockholm Large Cap.